Metsera: Capturing Of Obesity Market With Long-Acting GLP-1 Differentiation
Metsera's IPO raised $316.2 million, funding its obesity drug MET-097i, which shows promise with once-monthly dosing. Read ...
Wall Street bullish on Metsera following January IPO on obesity drug pipeline
Wall Street analysts initiated coverage on Metsera with bullish outlook given the biotech firm’s differentiated obesity drug pipeline and potential for significant upside. Metsera is also viewed as a ...
MedCity News28d
Metsera’s IPO Raises $275M to Show How Its Obesity Drugs Can Top Current GLP-1s
Metsera has technologies and drug candidates intended to improve on these limitations. With key clinical trial readouts expected this year, the company took its story to investors through an IPO.
This weight-loss drug stock could deliver a 90% return in 2025
Guggenheim analyst sees significant upside in Metsera stock to $56. MTSR is working on both injectable and oral weight-loss ...
Dealbreaker on MSN26d
Metsera’s IPO Raises $275M to Show How Its Obesity Drugs Can Top Current GLP-1s
Drugs that activate the GLP-1 receptor transformed the treatment of obesity, but biotech company Metsera contends that ...
Investing5d
Cantor Fitzgerald initiates Metsera with overweight rating
In other recent news, Metsera Inc has made significant strides with its initial public offering (IPO), which opened 42% higher than its offering price. The company initially set its IPO at $18.00 ...
MarketWatch29d
Obesity-drug maker Metsera posts largest gain as IPOs defy market swoon
At the closing bell, Metsera’s stock MTSR stood at $26.50, well above its IPO pricing level of $18. It opened on the Nasdaq at $25.50. Back To Top ...
Investing5d
Cantor Fitzgerald initiates Metsera with overweight rating
In other recent news, Metsera Inc has made significant strides with its initial public offering (IPO), which opened 42% higher than its offering price. The company initially set its IPO at $18.00 per ...